lobbying_activities
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
1,225 rows where filing_year = 2024 and issue_code = "MED" sorted by filing_year descending
This data as json, CSV (advanced)
Suggested facets: filing_type, is_termination, received_date (date)
| id | filing_uuid | filing_type | registrant_name | registrant_id | client_name | filing_year ▲ | filing_period | issue_code | specific_issues | government_entities | income_amount | expense_amount | is_no_activity | is_termination | received_date |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3138214 | MARSHALL BRACHMAN eb9272e6-8646-4861-ac60-a90bcde2db9f | 1T | MARSHALL BRACHMAN | 6848 | BAYLOR SCOTT AND WHITE HEALTH -- FORMERLY BAYLOR HEALTH CARE SYSTEM | 2024 | first_quarter | MED | support funding for medical research programs | HOUSE OF REPRESENTATIVES,SENATE | 24000 | 0 | 1 | 2024-03-05T14:56:16-05:00 | |
| 3138459 | REPUBLIC CONSULTING, LLC e776dab9-33ed-4096-9150-37da7e408176 | Q1 | REPUBLIC CONSULTING, LLC | 401016871 | IQVIA | 2024 | first_quarter | MED | Monitor Health Data Policy. | Executive Office of the President (EOP),HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2024-03-29T12:19:47-04:00 | |
| 3138489 | FRANCIS EDWARD & CRONIN, INC. b7016781-bfad-4ed8-8f20-dd49658edb33 | Q1 | FRANCIS EDWARD & CRONIN, INC. | 311314 | CURE ALZHEIMER'S FUND | 2024 | first_quarter | MED | Legislation related to Alzheimer's disease research | Environmental Protection Agency (EPA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE | 20000 | 0 | 0 | 2024-03-31T12:22:42-04:00 | |
| 3138490 | FRANCIS EDWARD & CRONIN, INC. 5cffa855-209f-4538-9972-dc9154aee29e | Q1 | FRANCIS EDWARD & CRONIN, INC. | 311314 | USAGAINSTALZHEIMER'S | 2024 | first_quarter | MED | Legislation related to the treatment, detection, and prevention of Alzheimer's disease | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2024-03-31T12:24:32-04:00 | |
| 3138499 | HASHEMI STRATEGIC ADVISORS c65b5ff7-b3cb-495e-ba1c-80905c1c7ee4 | 1T | HASHEMI STRATEGIC ADVISORS | 401108007 | ULTRAGENYX | 2024 | first_quarter | MED | Rare and Ultrarare genetic diseases | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 1 | 2024-04-01T00:09:17-04:00 | |
| 3138586 | HELIX, INC. ca351427-ce8d-4a70-805e-e13ac3dc1ded | Q1 | HELIX, INC. | 401106164 | HELIX, INC. | 2024 | first_quarter | MED | Oversight of Lab Developed Tests, express legislative authority. Viral Surveillance in clinical settings. | Centers For Disease Control & Prevention (CDC),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE | 83000 | 0 | 0 | 2024-04-01T11:07:53-04:00 | |
| 3138817 | RAY C CULVER III 186e6ef5-3176-41ab-928f-e390915b9394 | Q1 | RAY C CULVER III | 11468 | ARKANSAS CHILDREN'S HOSPITAL | 2024 | first_quarter | MED | Funding for USDA ARS human nutrition research funding in the Consolidated Appropriations Act, 2024, and in the FY2025 appropriation bills. | HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2024-04-01T20:36:31-04:00 | |
| 3138824 | OCAL LOBBYING GROUP 35e5d816-4f5e-4b6d-a30e-cb9a0af259e5 | Q1 | OCAL LOBBYING GROUP | 401106825 | SAMERA S.A. | 2024 | first_quarter | MED | Obtain funding for Tuberculosis monitoring. | Natl Institutes of Health (NIH) | 0 | 0 | 2024-04-02T07:25:38-04:00 | ||
| 3138892 | AUBURN HEALTH STRATEGIES, LLC d7924075-9e85-46d3-8e76-f5bb55176357 | Q1 | AUBURN HEALTH STRATEGIES, LLC | 292697 | AMERICAN PROFICIENCY INSTITUTE | 2024 | first_quarter | MED | proficiency testing for clinical laboratories | 0 | 0 | 2024-04-02T10:47:58-04:00 | |||
| 3138970 | EMERGENT STRATEGIES 7655a53f-5a73-429a-9071-b068e696c7ff | Q1 | EMERGENT STRATEGIES | 401104778 | ADVAMED:ADVANCED MEDICAL TECHNOLOGY ASSOCIATION | 2024 | first_quarter | MED | Health tax issues and trade, Issues related to Small Business Innovation Research Program. PAHPA Reauthorization | HOUSE OF REPRESENTATIVES,SENATE | 45000 | 0 | 0 | 2024-04-02T13:46:56-04:00 | |
| 3138979 | AMERICAN COLLEGE OF CLINICAL PHARMACY e7423c4b-9da7-41ca-8098-5280709b1e59 | Q1 | AMERICAN COLLEGE OF CLINICAL PHARMACY | 57258 | AMERICAN COLLEGE OF CLINICAL PHARMACY | 2024 | first_quarter | MED | Focus interactions with the Agency for Healthcare Research and Quality (AHRQ) on the issue of Quality of Medication Therapy Management Services delivered programs authorized by the Patient Protection and Affordable Care Act (PPACA PL 111-148) and Medicare Part D plans. | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 144981 | 0 | 0 | 2024-04-02T13:50:47-04:00 | |
| 3139014 | O'NEILL AND ASSOCIATES af595c6f-5db0-4521-a990-d5dd74c8aa98 | Q1 | O'NEILL AND ASSOCIATES | 73134 | POINT32HEALTH SERVICES, INC. (FORMERLY TUFTS HEALTH PLAN) | 2024 | first_quarter | MED | Healthcare, Medical | HOUSE OF REPRESENTATIVES,SENATE | 15000 | 0 | 0 | 2024-04-02T14:55:59-04:00 | |
| 3139029 | MAGILL ASSOCIATES, LLC 3968df92-ea40-419d-8bc9-69e521cbdcd9 | Q1 | MAGILL ASSOCIATES, LLC | 401103511 | THE LIVINGSTON GROUP ON BEHALF OF INNOVATIVE VACCINE TECHNOLOGIES | 2024 | first_quarter | MED | FY 2024 and FY 2025 appropriations for the development of a synthetic vaccine | Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES | 20000 | 0 | 0 | 2024-04-02T15:43:31-04:00 | |
| 3139043 | THE DLM GROUP cc2f96e2-744c-4e42-bd38-b4213fbbf0dc | Q1 | THE DLM GROUP | 313794 | GENESIS HEALTH CARE, INC. | 2024 | first_quarter | MED | no activity | HOUSE OF REPRESENTATIVES,SENATE | 15000 | 0 | 0 | 2024-04-02T15:59:10-04:00 | |
| 3139130 | THE HARRIS FIRM 59b20070-c91f-4b2d-8ad7-328ef970fa80 | Q1 | THE HARRIS FIRM | 68376 | HOLISTIC INDUSTRIES INC. | 2024 | first_quarter | MED | Issues pertaining to cannabis CSA scheduling. | Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2024-04-02T16:49:20-04:00 | |
| 3139411 | LOBBYIT.COM 661f5a27-e854-48ac-baca-763a89f8ddf1 | Q1 | LOBBYIT.COM | 400487397 | BRAIN ANEURYSM FOUNDATION | 2024 | first_quarter | MED | Advocate for the passage of Ellie's Law (H.R. 902, S. 895) Creation of a dedicated Brain Aneurysm Caucus Appropriation Requests | HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2024-04-03T14:16:19-04:00 | |
| 3139625 | SQUIRE PATTON BOGGS 230da5aa-3dfa-4ecf-9048-a39ff417586a | Q1 | SQUIRE PATTON BOGGS | 30906 | ALLIANCE FOR BIOSECURITY | 2024 | first_quarter | MED | Preparedness and response as it relates to Biosecurity. | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office | 80000 | 0 | 0 | 2024-04-04T09:43:53-04:00 | |
| 3139870 | CAPSTONE NATIONAL PARTNERS 00e54f12-f3a5-4291-a2dc-87eea70b1c28 | Q1 | CAPSTONE NATIONAL PARTNERS | 8214 | ATTERX BIOTHERAPEUTICS | 2024 | first_quarter | MED | research funding | HOUSE OF REPRESENTATIVES,SENATE | 15000 | 0 | 0 | 2024-04-04T15:17:42-04:00 | |
| 3139887 | HADASSAH, THE WOMEN'S ZIONIST ORGANIZATION OF AMERICA, INC. b3798696-7417-415a-b9d9-5e076d73ac36 | Q1 | HADASSAH, THE WOMEN'S ZIONIST ORGANIZATION OF AMERICA, INC. | 52925 | HADASSAH, THE WOMEN'S ZIONIST ORGANIZATION OF AMERICA, INC. | 2024 | first_quarter | MED | MED HR 3226/S 1573: Prematurity Research Expansion and Education for Mothers who Deliver Infants Early (PREEMIE) Reauthorization Act of 2023 All Provisions This bill would reauthorize critical federal research, education and care to reduce preterm birth and infant mortality. MED HR 4534/S 2245 - Women and Lung Cancer Research and Preventative Services Act of 2023 All provisions This bill requires a review of women and lung cancer. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2024-04-04T15:36:35-04:00 | |
| 3139917 | FEDERAL SOLUTIONS, LLC 7c651ae4-0a98-48a0-829a-6c1943dd6113 | Q1 | FEDERAL SOLUTIONS, LLC | 311371 | MISSISSIPPI STATE UNIVERSITY | 2024 | first_quarter | MED | Labor/HHS/Education Appropriations: Provisions relating to disease research | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2024-04-04T17:26:14-04:00 | |
| 3140296 | BEN BARNES GROUP LP 08dcda5f-80a7-406b-85fb-a1cbbb6ce579 | Q1 | BEN BARNES GROUP LP | 5415 | HUNTSMAN CORPORATION | 2024 | first_quarter | MED | CMS Medicare | HOUSE OF REPRESENTATIVES,SENATE | 18750 | 0 | 0 | 2024-04-07T13:13:35-04:00 | |
| 3140300 | BEN BARNES GROUP LP 36239305-e95e-4b47-b22a-446f60c6f555 | Q1 | BEN BARNES GROUP LP | 5415 | ENVIGO RMS LLC | 2024 | first_quarter | MED | Medical/Disease Research | SENATE | 11500 | 0 | 0 | 2024-04-07T13:25:16-04:00 | |
| 3140305 | BEN BARNES GROUP LP c91aab78-e16f-41dc-ac1a-ce5a7b564ac0 | Q1 | BEN BARNES GROUP LP | 5415 | CLENE NANOMEDICINE, INC. | 2024 | first_quarter | MED | ALS | HOUSE OF REPRESENTATIVES,SENATE | 100000 | 0 | 0 | 2024-04-07T13:44:56-04:00 | |
| 3140465 | THE CONSILIO GROUP 70eec3d9-1da0-4ec5-bee3-0f0e4d5c2c7c | Q1 | THE CONSILIO GROUP | 400374717 | DETECTACHEM | 2024 | first_quarter | MED | Colorimetric explosive and narcotic detection capabilities | Air Force, Dept of,Defense, Dept of (DOD),Education, Dept of,Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Navy, Dept of,SENATE,White House Office | 16500 | 0 | 0 | 2024-04-08T10:44:31-04:00 | |
| 3140520 | WATKINS & EAGER PLLC 30301792-954e-40a4-a8dc-9d0797a7170d | Q1 | WATKINS & EAGER PLLC | 401104403 | NATIONAL FRAGILE X FOUNDATION | 2024 | first_quarter | MED | Assist in matters necessary for Advocacy Day planning on The Hill; Arrange meetings and appointments for NFXF officials; Work to encourage Members to act favorably on matters of interest and benefit to NFXF; Encourage Members to meet with constituents impacted by Fragile X. | HOUSE OF REPRESENTATIVES,SENATE | 15000 | 0 | 0 | 2024-04-08T11:35:51-04:00 | |
| 3140558 | FONTENOT HEALTH POLICY LLC 56935300-8300-47fe-946c-4609da53300d | Q1 | FONTENOT HEALTH POLICY LLC | 401107703 | ORGANIZE DBA ORGANIZE ACTION NETWORK | 2024 | first_quarter | MED | Organ Procurement reforms; Revisions to the Outcme Measure Requirements for Organ Procurement Organizations; Final Rule (42 CFR, Part 486); Organ Procurement Organizations Conditions of Coverage; S. 1688/H.R. 2544 Securing the U.S. Organ Procurement and Transplantation Network Act | 10000 | 0 | 0 | 2024-04-08T12:17:12-04:00 | ||
| 3140638 | BARKER LEAVITT, PLLC (SKA MR. JAMES C. BARKER) b5b495ee-5fe2-4caf-9003-682171b170b9 | Q1 | BARKER LEAVITT, PLLC (SKA MR. JAMES C. BARKER) | 292538 | SONIC HEALTHCARE USA | 2024 | first_quarter | MED | Issues relating to the regulation of laboratory developed tests, the VALID Act, issues relating to PAMA (the SALSA Bill), federal policies relating to the implementation of the anti-kickback requirements of the Support for Patients and Communities Act. Physician Lab Fee schedule. Anatomic Fee Schedule and Surprise Billing. COVID Testing and billing procedures. COVID Vaccine Federal Mandate. | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2024-04-08T14:25:18-04:00 | |
| 3140652 | MCDERMOTT+ LLC 8ef2e13b-aeb3-43b4-92ab-98d3b199a81f | Q1 | MCDERMOTT+ LLC | 401103287 | VERILY LIFE SCIENCES LLC | 2024 | first_quarter | MED | Efforts relating to artificial intelligence, wastewater surveillance and drug and device innovation. | Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2024-04-08T14:33:16-04:00 | ||
| 3140763 | 2359 STRATEGIES 9901c974-9530-4210-a8ee-c8a75fc674da | Q1 | 2359 STRATEGIES | 401106114 | TRAVERE THERAPEUTICS | 2024 | first_quarter | MED | Rare kidney disease | HOUSE OF REPRESENTATIVES,SENATE | 12000 | 0 | 0 | 2024-04-08T20:03:07-04:00 | |
| 3141118 | MASON STREET CONSULTING, LLC 6654a24c-e811-43a5-88bb-2122dc01dc80 | Q1 | MASON STREET CONSULTING, LLC | 401105150 | PERIMETER MEDICAL IMAGING | 2024 | first_quarter | MED | Advanced Research Projects Agency for Health (ARPA-H). | Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2024-04-09T14:34:30-04:00 | |
| 3141241 | TRUSYNERGY 0c3fda88-cb4d-41d4-be54-dcc8df9ff64f | Q1 | TRUSYNERGY | 401107715 | BURRELL INTERNATIONAL GROUP (ON BEHALF OF ARSENAL MEDICAL, INC.) | 2024 | first_quarter | MED | Funding for medical devices for hemorrhages; provisions in FY24 NDAA and FY24 Defense Appropriations | HOUSE OF REPRESENTATIVES,SENATE | 5000 | 0 | 0 | 2024-04-10T06:29:24-04:00 | |
| 3141301 | SQUIRE PATTON BOGGS 684a0ce4-ba15-4d20-b63f-d88fb9d1d7b2 | Q1 | SQUIRE PATTON BOGGS | 30906 | LA MAESTRA FOUNDATION ON BEHALF OF LA MAESTRA FAMILY CLINIC, INC. | 2024 | first_quarter | MED | Funding support for federally qualified health centers; reauthorization of programs | HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2024-04-10T11:09:24-04:00 | |
| 3141368 | TRUSYNERGY 53ada252-806b-499d-8919-a73475338f8a | Q1 | TRUSYNERGY | 401107715 | BURRELL INTERNATIONSL GROUP (ON BEHALF OF OTOGENETICS) | 2024 | first_quarter | MED | Funding for genetic testing and carrier screening, women's health, diagnostic equity, FY 24 appropriations, FY 25 appropriations, FY 25 NDAA | Defense, Dept of (DOD) | 0 | 0 | 2024-04-10T12:32:35-04:00 | ||
| 3141389 | ASSOCIATION FOR DIAGNOSTICS & LABORATORY MEDICINE (FORMERLY AACC) a1b89058-6baf-4373-9a92-3148a5742afa | Q1 | ASSOCIATION FOR DIAGNOSTICS & LABORATORY MEDICINE (FORMERLY AACC) | 1466 | ASSOCIATION FOR DIAGNOSTICS & LABORATORY MEDICINE (FORMERLY AACC) | 2024 | first_quarter | MED | * On January 24, ADLM and the American Society for Microbiology wrote to the Centers for Medicare and Medicaid Services requesting that the agency reconsider its decision to recognize a Doctorate in Clincal Laboratory Science as an accepted PhD for high complexity laboratory directors under the CLIA regulations. *On March 18, ADLM met with, and submitted comments to, Office of Management and Budget staff in opposition to the release of the Food and Drug Administration final rule on laboratory developed tests. * On March 21, ADLM submitted testimony to the House Energy and Commerce Committee Subcommittee on Health raising concerns about FDA oversight of LDTs. | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB) | 50000 | 0 | 0 | 2024-04-10T13:46:35-04:00 | |
| 3141918 | UNIVERSITY OF MARYLAND, BALTIMORE (UMB) 5a89e603-12ca-4295-a077-cf0b3e00b1be | Q1 | UNIVERSITY OF MARYLAND, BALTIMORE (UMB) | 401103161 | UNIVERSITY OF MARYLAND, BALTIMORE (UMB) | 2024 | first_quarter | MED | NONE | 10000 | 0 | 0 | 2024-04-11T12:16:44-04:00 | ||
| 3142534 | PARALYZED VETERANS OF AMERICA 3ae40d67-c4d1-451e-acd2-b4147f8e5677 | Q1 | PARALYZED VETERANS OF AMERICA | 30724 | PARALYZED VETERANS OF AMERICA | 2024 | first_quarter | MED | Discussions: Department of Veterans Affairs, Medical Research Issues Discussions: National Institutes of Health, Medical Research Issues | HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE,Veterans Affairs, Dept of (VA) | 74465 | 0 | 0 | 2024-04-12T11:49:24-04:00 | |
| 3142721 | TIBER CREEK GROUP dc84415d-a6e7-4a55-9dce-e0c9ffb05935 | Q1 | TIBER CREEK GROUP | 20744 | JAZZ PHARMACEUTICALS | 2024 | first_quarter | MED | Issues related to cannabis research; Issues related to the FDA; Issues related to cannabis research at Health and Human Services. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2024-04-12T13:46:53-04:00 | |
| 3142916 | OLD NORTH STRATEGIES, LLC c62267ab-b70a-4d04-963f-d1540852cda6 | Q1 | OLD NORTH STRATEGIES, LLC | 401106174 | EXELA PHARMA SCIENCES, LLC | 2024 | first_quarter | MED | supply chain & FDA issues | HOUSE OF REPRESENTATIVES,SENATE | 108000 | 0 | 0 | 2024-04-12T16:14:35-04:00 | |
| 3143267 | FORBES-TATE e353961c-d642-43c7-b862-dae7cda04fca | Q1 | FORBES-TATE | 400976792 | CALIFORNIA LIFE SCIENCES ASSOCIATION | 2024 | first_quarter | MED | Issues related to the life sciences industry; Issues related to drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169). | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2024-04-12T19:30:12-04:00 | |
| 3143295 | FORBES-TATE e4b7414e-4bc5-466e-bd27-ecfb3b7b77d4 | Q1 | FORBES-TATE | 400976792 | COALITION FOR CANNABIS POLICY, EDUCATION, AND REGULATION | 2024 | first_quarter | MED | Issues pertaining to government-wide federal regulation of cannabis. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2024-04-12T19:50:19-04:00 | |
| 3143316 | CORNERSTONE GOVERNMENT AFFAIRS, INC. 081f1c72-ed1a-463e-af6b-73c90f70c556 | Q1 | CORNERSTONE GOVERNMENT AFFAIRS, INC. | 75557 | HAZELDEN BETTY FORD FOUNDATION | 2024 | first_quarter | MED | Educate key government stakeholders on Hazelden Betty Ford Foundation activities in support of substance use and mental health for US Service members and Veterans. | Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2024-04-12T20:20:59-04:00 | |
| 3143395 | FORBES-TATE 64a0bbc3-1f8a-4922-9a46-fcecfd7257dc | Q1 | FORBES-TATE | 400976792 | CSL BEHRING | 2024 | first_quarter | MED | Issues related to Rx pricing; Issues related to plasma and plasma derived therapies; Issues related to H.R. - 6465 Preserving Life-saving Access to Specialty Medicines in America Act. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2024-04-12T21:10:20-04:00 | |
| 3143400 | CORNERSTONE GOVERNMENT AFFAIRS, INC. 05d13112-16d4-4000-9e7e-2fef5bf7698d | Q1 | CORNERSTONE GOVERNMENT AFFAIRS, INC. | 75557 | OU MEDICINE, INC. | 2024 | first_quarter | MED | Research and development of medical programs in partnership with Department of Health and Human Services and other federal agencies | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2024-04-12T21:13:40-04:00 | |
| 3143449 | CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER 1b9ee0db-1be8-4495-a398-984eb3f8c550 | Q1 | CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER | 312496 | CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER | 2024 | first_quarter | MED | NIH funding, PACT Act, Accelerating Kids Access Act, NIH reform Senate HELP Minority RFI, genomic testing, LDT testing FDA rule, NICHD workforce reform including K12 | Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE,White House Office | 35600 | 0 | 0 | 2024-04-13T09:16:53-04:00 | |
| 3143605 | CHAMBER HILL STRATEGIES 1e416e05-f53c-48b1-a41b-af8a0276d87d | Q1 | CHAMBER HILL STRATEGIES | 400645947 | MAYO COLLABORATIVE SERVICES, INC. | 2024 | first_quarter | MED | Issues impacting diagnostics including FDA regulation of laboratory developed tests; H.R.2369, VALID Act of 2023. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2024-04-13T17:17:20-04:00 | |
| 3143936 | FORBES-TATE 100d0167-fb20-428f-9737-1f5d1acc3da6 | Q1 | FORBES-TATE | 400976792 | AMERICAN COLLEGE OF RADIOLOGY ASSOCIATION | 2024 | first_quarter | MED | Issues related to Medicare and Medicaid payments to physicians; Issues related to medical imaging. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2024-04-14T12:26:33-04:00 | |
| 3144059 | CORNERSTONE GOVERNMENT AFFAIRS, INC. 9458addc-28e1-4c69-ad88-38f5d6d17fbf | Q1 | CORNERSTONE GOVERNMENT AFFAIRS, INC. | 75557 | ADVANCED MEDICAL TECHNOLOGY ASSOCIATION | 2024 | first_quarter | MED | Congressional outreach related to health care issues. | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2024-04-14T18:05:38-04:00 | |
| 3144072 | THE PETRIZZO GROUP, INC. f046ec2a-3324-4ad0-a507-d6b2dce9d6e3 | Q1 | THE PETRIZZO GROUP, INC. | 305932 | OMEROS CORPORATION | 2024 | first_quarter | MED | Development and execution of initiatives involving multiple Omeros pipeline targets before the U.S. Government, including funding collaborations associated with COVID, Cancer, and addition within the Department of HHS, NIH, BARDA, and the White House. | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE | 75000 | 0 | 0 | 2024-04-14T18:13:00-04:00 | |
| 3144180 | FORBES-TATE cdfab3a0-b4ff-4914-be3b-787af7e47f61 | Q1 | FORBES-TATE | 400976792 | AMGEN USA, INC. | 2024 | first_quarter | MED | Issues related to Biosimilars; Issues related to drug pricing; Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program. | HOUSE OF REPRESENTATIVES,SENATE | 80000 | 0 | 0 | 2024-04-14T21:03:02-04:00 | |
| 3144436 | WILLIAM SCHMIDT 7513a8a3-9cb0-486f-8490-e38f5caa81f7 | Q1 | WILLIAM SCHMIDT | 401107557 | PULMONARY FIBROSIS FOUNDATION | 2024 | first_quarter | MED | Funding for the National Institutes of Health Funding for the Congressionally Directed Medical Research Program at the Department of Defense | HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2024-04-15T09:02:58-04:00 | ||
| 3144466 | IPOLICY SOLUTIONS 8d195101-09b9-4eb1-8a87-1fc2e1bb71e3 | Q1 | IPOLICY SOLUTIONS | 401105127 | ASSOCIATION FOR MOLECULAR PATHOLOGY | 2024 | first_quarter | MED | No bill #: legislation to modernize CLIA H.R.2369 - VALID Act of 2023 FDA Proposed Rulemaking on LDTs | HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE | 70500 | 0 | 0 | 2024-04-15T09:44:32-04:00 | |
| 3144477 | IPOLICY SOLUTIONS 3a8b334a-d4f9-43a2-850b-66b9332ccda3 | Q1 | IPOLICY SOLUTIONS | 401105127 | INVITAE INC. | 2024 | first_quarter | MED | H.R.2369 - VALID Act of 2023 FDA Proposed rule on LDTs | HOUSE OF REPRESENTATIVES,Office of Science & Technology Policy (OSTP),SENATE | 40000 | 0 | 0 | 2024-04-15T09:50:14-04:00 | |
| 3144624 | TENAGRITY SOLUTIONS, LLC 0d888fc1-4e0c-4dd6-bf91-a9bd7c6467c4 | Q1 | TENAGRITY SOLUTIONS, LLC | 401107856 | KARDIOGENICS, INC. | 2024 | first_quarter | MED | Preparation to introduce client to congressional offices re: how their health work can help with defense | HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2024-04-15T11:06:07-04:00 | ||
| 3144633 | TENAGRITY SOLUTIONS, LLC 510c0c32-b562-4d94-b8b7-526e020127dd | Q1 | TENAGRITY SOLUTIONS, LLC | 401107856 | 1DAY SOONER ACTION PROJECT | 2024 | first_quarter | MED | S. 2333, Pandemic and All-Hazards Preparedness and Response Act (Hickenlooper - Budd Amendment to establish an emerging pathogen preparedness program through the FDA); FY24 & FY25 appropriations to ensure adequate resources for HHS for pandemic preparedness. Discussions with House and Senate offices about potential new legislation related to how the government encourages innovation in health care and other industries. Assistance with a letter of support to HHS, encouraging the establishment of an emerging pathogen preparedness program through the FDA Assistance with a letter of support from the US House (and pursuing one from the Senate) to the White House re: recent malaria vaccine developments; other interactions with the WH, HHS, and DoD to promote prompt distribution of malaria vaccines . To support the FDA - DoD relationship to prioritize the development of safe and effective medical products that could save military personnel lives | Defense, Dept of (DOD),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office | 20000 | 0 | 0 | 2024-04-15T11:28:00-04:00 | |
| 3144868 | FGS GLOBAL (US) LLC (FKA FGH HOLDINGS LLC) 0cd49e77-9739-4df0-b6f7-ed3357274dcc | Q1 | FGS GLOBAL (US) LLC (FKA FGH HOLDINGS LLC) | 86196 | INTUITIVE SURGICAL, INC. | 2024 | first_quarter | MED | Lobbying related to health care issues. | HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2024-04-15T12:52:02-04:00 | |
| 3145045 | AMERICAN SOCIETY OF CONSULTANT PHARMACISTS 915d4b15-2fad-486e-af7e-e4a47b83816e | Q1 | AMERICAN SOCIETY OF CONSULTANT PHARMACISTS | 3446 | AMERICAN SOCIETY OF CONSULTANT PHARMACISTS | 2024 | first_quarter | MED | Warning label transparency and evaluation process Medication and vaccine access Clinical trial diversity and equity | Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE | 15000 | 0 | 0 | 2024-04-15T13:55:30-04:00 | |
| 3145055 | THE CONSILIO GROUP 7389894e-6d6d-4efe-b194-ebdf3d994b5f | 1A | THE CONSILIO GROUP | 400374717 | DETECTACHEM | 2024 | first_quarter | MED | Colorimetric explosive and narcotic detection capabilities | Air Force, Dept of,Defense, Dept of (DOD),Education, Dept of,Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Navy, Dept of,SENATE,White House Office | 16500 | 0 | 0 | 2024-04-15T13:58:48-04:00 | |
| 3145080 | IMPACT MANAGEMENT GROUP ae7c0b42-46cd-4d49-beae-a8a23e91bf1b | Q1 | IMPACT MANAGEMENT GROUP | 401104137 | ARKANSAS RESEARCH ALLIANCE | 2024 | first_quarter | MED | On behalf of client support continued and future funding for clinical research programs in Arkansas | HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2024-04-15T14:15:29-04:00 | ||
| 3145118 | IMPACT MANAGEMENT GROUP 2abcf7a0-cc26-431c-a5f0-2680766740b5 | Q1 | IMPACT MANAGEMENT GROUP | 401104137 | CENTRAL ARKANSAS RADIATION THERAPY INSTITUTE, INC. | 2024 | first_quarter | MED | Supporting the passage of H.R. 3173 - Improving Seniors' Timely Access to Care Act of 2021 | HOUSE OF REPRESENTATIVES | 0 | 0 | 2024-04-15T14:28:11-04:00 | ||
| 3145306 | CORNERSTONE GOVERNMENT AFFAIRS, INC. ade4c6b9-f42f-4f35-93f7-ad9bb491df34 | Q1 | CORNERSTONE GOVERNMENT AFFAIRS, INC. | 75557 | AMERICAN SOCIETY FOR RADIATION ONCOLOGY | 2024 | first_quarter | MED | Discussions regarding patient access to radiation oncology. | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES | 50000 | 0 | 0 | 2024-04-15T15:40:16-04:00 | |
| 3145407 | THE LIVINGSTON GROUP, LLC d5f11fee-e27b-4f90-a5ac-6806366daab4 | Q1 | THE LIVINGSTON GROUP, LLC | 49635 | INNOVATIVE VACCINE TECHNOLOGIES | 2024 | first_quarter | MED | FY2024 and FY2025 appropriations for the development of a synthetic vaccine | Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES | 30000 | 0 | 0 | 2024-04-15T16:16:14-04:00 | |
| 3145600 | CORNERSTONE GOVERNMENT AFFAIRS, INC. 1689c9b8-3937-43e0-8494-e65cd6267f9e | Q1 | CORNERSTONE GOVERNMENT AFFAIRS, INC. | 75557 | THE UNIVERSITY OF TEXAS SYSTEM | 2024 | first_quarter | MED | Assessing the Systems R&D funding opportunities, designing strategies to pursue funding, and securing funding for research priorities. | HOUSE OF REPRESENTATIVES,SENATE | 90000 | 0 | 0 | 2024-04-15T17:12:59-04:00 | |
| 3145769 | COVINGTON & BURLING LLP 50d97a55-2068-4188-bcb9-201541b2d12f | Q1 | COVINGTON & BURLING LLP | 11195 | RWE ALLIANCE INC. | 2024 | first_quarter | MED | Real-world health data and analytics policy. | 60000 | 0 | 0 | 2024-04-15T19:05:32-04:00 | ||
| 3145852 | ALPINE ADVISORS 597e4313-8f59-43d3-ba0b-513b3e9c050b | Q1 | ALPINE ADVISORS | 401106595 | COALITION FOR CANNABIS POLICY, EDUCATION AND REGULATION | 2024 | first_quarter | MED | Issues pertaining to government-wide federal regulation of cannabis | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2024-04-16T06:52:21-04:00 | |
| 3145916 | EFB ADVOCACY, LLC b3063f03-092a-4354-9bd8-4de743eaa8f8 | Q1 | EFB ADVOCACY, LLC | 401104430 | UNITED FOR MEDICAL RESEARCH | 2024 | first_quarter | MED | Funding Issues related to the National Institutes of Health | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2024-04-16T09:33:24-04:00 | |
| 3146553 | THE JACKSON LABORATORY 94a5d184-aefe-4704-b1e5-ea2d44ddad57 | Q1 | THE JACKSON LABORATORY | 401104723 | THE JACKSON LABORATORY | 2024 | first_quarter | MED | Issues related to biomedical research. Animal model use in biomedical research. | HOUSE OF REPRESENTATIVES,Office of Science & Technology Policy (OSTP),SENATE | 30000 | 0 | 0 | 2024-04-16T13:50:07-04:00 | |
| 3146663 | NATIONAL ASSOCIATION FOR BIOMEDICAL RESEARCH 8ce7fbfe-4dfc-435d-b80d-3f9a3b5a6f9a | Q1 | NATIONAL ASSOCIATION FOR BIOMEDICAL RESEARCH | 26557 | NATIONAL ASSOCIATION FOR BIOMEDICAL RESEARCH | 2024 | first_quarter | MED | Support funding for biomedical research | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2024-04-16T14:20:17-04:00 | |
| 3147285 | TIDES GROUP, LLC 58751405-0e86-4fd6-8b39-188998573537 | 1T | TIDES GROUP, LLC | 401105835 | AGENUS INC. | 2024 | first_quarter | MED | Issues related to colorectal cancer immunotherapy. | HOUSE OF REPRESENTATIVES | 30000 | 0 | 1 | 2024-04-16T16:30:48-04:00 | |
| 3147326 | ARENTFOX SCHIFF LLP a53c33cc-3000-4698-b52b-b5051662d584 | Q1 | ARENTFOX SCHIFF LLP | 4208 | INFECTIOUS DISEASES SOCIETY OF AMERICA | 2024 | first_quarter | MED | H.R. 2940 and S. 1355 (PASTEUR Act of 2023), all provisions H.R. 4420 (Preparedness and Response Reauthorization Act), all provisions H.R. 4421 (Preparing for all Hazards and Pathogens Reauthorization Act), all provisions S. 2333 (Pandemic and All-Hazards Preparedness and Response Act), all provisions | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2024-04-16T16:39:13-04:00 | |
| 3148119 | JEFFREY J. KIMBELL & ASSOCIATES, INC. 7273421b-b1bc-43f0-a6db-264406663b6a | Q1 | JEFFREY J. KIMBELL & ASSOCIATES, INC. | 46038 | ANIVIVE LIFESCIENCES | 2024 | first_quarter | MED | issues related to Valley Fever and fungal vaccines | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2024-04-17T11:14:25-04:00 | |
| 3148533 | AMERICAN PHYSICAL THERAPY ASSOCIATION a86b845b-d749-4cb2-8b17-8cc100831e30 | Q1 | AMERICAN PHYSICAL THERAPY ASSOCIATION | 3093 | AMERICAN PHYSICAL THERAPY ASSOCIATION | 2024 | first_quarter | MED | NIH Rehab issues APTA role with NIH Traumatic brain injury research Support of work done at CDC Injury Center on elder adult falls, TBI, youth sports concussions NIH Research and Development funding PT role in childhood obesity Relocate TBI State Grant Program to ACL NIDILRR - Rehab research Nomination to NIH Committees Safety of Children in School (Restraint & Seclusion) Falls and Falls Prevention | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE | 277054 | 0 | 0 | 2024-04-17T12:38:56-04:00 | |
| 3149143 | UNIVERSITY OF KENTUCKY 54120e20-0ac6-4ae6-9c5a-8ebe392aa006 | Q1 | UNIVERSITY OF KENTUCKY | 400287372 | UNIVERSITY OF KENTUCKY | 2024 | first_quarter | MED | Barriers to research with Schedule 1 drugs NCI funding for FY24 | HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE | 184323 | 0 | 0 | 2024-04-17T14:52:07-04:00 | |
| 3149339 | F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES a5a5f5e5-cab8-44c4-8dd6-3c2d31e81bac | Q1 | F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES | 18411 | F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES | 2024 | first_quarter | MED | H.R. 2369 The Verifying Accurate Leading-edge IVCT Development Act, Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R. 3795 The Diagnostics Testing Preparedness Plan Act, H.R. 3631 The State Stockpile Act, H. R. 5846 Protecting America from Seasonal and Pandemic, Influenza Act of 2023 (the Influenza Act) Clinical Lab Fee Schedule H.R. 2377 and S. 1000. Saving Access to Laboratory Services Act (SALSA) and 1691 the Ensuring Patient Access to Critical Breakthrough Products Act of 2023 | HOUSE OF REPRESENTATIVES,SENATE | 180000 | 0 | 0 | 2024-04-17T15:36:20-04:00 | |
| 3149435 | BROWNSTEIN HYATT FARBER SCHRECK, LLP 91720acf-c9ad-43bc-9c11-bb4f00f20c2a | Q1 | BROWNSTEIN HYATT FARBER SCHRECK, LLP | 7257 | MARIDOSE LLC | 2024 | first_quarter | MED | Issues relating to cannabis research, including the DEA Aug. 12 2016 solicitation of applications to manufacture cannabis for research purposes (Docket No. DEA-447) | HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2024-04-17T16:01:26-04:00 | |
| 3149472 | UNIVERSITY OF GEORGIA a5478094-7184-4765-8c9c-52edb6825d53 | Q1 | UNIVERSITY OF GEORGIA | 40032283 | UNIVERSITY OF GEORGIA | 2024 | first_quarter | MED | Federal research funding | HOUSE OF REPRESENTATIVES,SENATE | 80000 | 0 | 0 | 2024-04-17T16:14:39-04:00 | |
| 3149553 | DA VINCI GROUP 49c0d06f-685c-489e-8425-3a851ad321d1 | Q1 | DA VINCI GROUP | 11548 | KAI MEDICAL LABORATORY | 2024 | first_quarter | MED | Funding for Clinical Research & Diagnostics Programs | HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2024-04-17T16:34:44-04:00 | |
| 3149838 | CORNERSTONE GOVERNMENT AFFAIRS, INC. df9d2982-03b5-4910-b374-b1616d8f5acc | Q1 | CORNERSTONE GOVERNMENT AFFAIRS, INC. | 75557 | CHILDREN'S NATIONAL MEDICAL CENTER | 2024 | first_quarter | MED | Health-related issues including reimbursement, research, public-health & clinical care. | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office | 50000 | 0 | 0 | 2024-04-17T18:03:43-04:00 | |
| 3150058 | IMPACT HEALTH POLICY PARTNERS 40b67b0a-d608-4427-9021-fe23f7ab6873 | Q1 | IMPACT HEALTH POLICY PARTNERS | 401104696 | ABBOTT LABORATORIES | 2024 | first_quarter | MED | Issues related to coverage and reimbursement for durable medical equipment, medical devices, diagnostics and nutrition. | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2024-04-18T08:17:13-04:00 | |
| 3150062 | IMPACT HEALTH POLICY PARTNERS c959412a-a15b-4d54-ad83-aafecd52f666 | Q1 | IMPACT HEALTH POLICY PARTNERS | 401104696 | CHILDREN'S HOSPITAL COLORADO | 2024 | first_quarter | MED | Issues related to pediatric research and children's hospital graduate medical education. | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2024-04-18T08:20:26-04:00 | |
| 3150068 | IMPACT HEALTH POLICY PARTNERS 1753ca9c-3564-4823-846b-46cbe3c62538 | Q1 | IMPACT HEALTH POLICY PARTNERS | 401104696 | HACKENSACK MERIDIAN HEALTH | 2024 | first_quarter | MED | Issues related to research funding, including ARPA-H, NIH, organ transplants, and other matters. | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office | 40000 | 0 | 0 | 2024-04-18T08:26:27-04:00 | |
| 3150192 | STANFORD UNIVERSITY 5560fed5-1064-4771-99c9-9d82acd21255 | Q1 | STANFORD UNIVERSITY | 36492 | STANFORD UNIVERSITY | 2024 | first_quarter | MED | HR 2389 Resident Physician Shortage Reduction Act of 2023 AI healthcare-related research Antiviral drug research / Antiviral Drug Discovery Centers | HOUSE OF REPRESENTATIVES,SENATE,Veterans Affairs, Dept of (VA) | 90000 | 0 | 0 | 2024-04-18T09:30:29-04:00 | |
| 3150408 | MANATT, PHELPS, AND PHILLIPS 0337355d-0a2e-463b-bb1e-6871cca0bca6 | Q1 | MANATT, PHELPS, AND PHILLIPS | 23645 | LOMA LINDA UNIVERSITY MEDICAL CENTER | 2024 | first_quarter | MED | Healthcare, Legislation Impacting Hospitals, Federal Funding/CPF and CDF | 140481 | 0 | 0 | 2024-04-18T10:22:35-04:00 | ||
| 3150423 | MANATT, PHELPS, AND PHILLIPS feb185f0-e7c0-4f69-8a1b-6b63ffdd4feb | Q1 | MANATT, PHELPS, AND PHILLIPS | 23645 | MEDISYS HEALTH NETWORK | 2024 | first_quarter | MED | Provider Relief and COVID funding and other healthcare issues; Community Project Funding | 44000 | 0 | 0 | 2024-04-18T10:25:24-04:00 | ||
| 3150597 | WILLIAMS AND JENSEN, PLLC 416ee0e5-de06-4225-a669-7eb6a252e4ef | Q1 | WILLIAMS AND JENSEN, PLLC | 41454 | THE JED FOUNDATION | 2024 | first_quarter | MED | General education about mental health and suicide prevention programs. | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2024-04-18T10:54:35-04:00 | |
| 3150693 | WILLIAMS AND JENSEN, PLLC b974dfc8-285c-40f0-a189-8defe6f906de | Q1 | WILLIAMS AND JENSEN, PLLC | 41454 | CALIFORNIA LIFE SCIENCES | 2024 | first_quarter | MED | General information about Medicare coverage and payment for drugs and devices including drug pricing legislation, "Inflation Reduction Act" implementation and changes including the EPIC Act and Orphan Cures Act, Pharmacy benefit manager reform proposals, and Medicare coverage for breakthrough devices. | HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2024-04-18T11:09:33-04:00 | |
| 3150737 | AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION c2302ec3-5f68-4b81-9d72-3eafe7abe468 | Q1 | AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION | 1331 | AMERICAN ACADEMY OF DERMATOLOGY ASSOCIATION | 2024 | first_quarter | MED | Advocate for medical research and prevention funding for the National Institutes of Health and Centers for Disease Control and Prevention via the FY2024 Labor, Health and Human Services, Education and Related Agencies Appropriations bill (H.R.5894/S.2624. Advocate for Defense Health Research Programs (CDMRP) in the FY24 Defense Appropriations Act, specifically the Melanoma Research Program (MRP) (H.R.4635/S.2587). Support H.R.3503,NIH Clinical Trial Diversity Act. | HOUSE OF REPRESENTATIVES,SENATE | 700000 | 0 | 0 | 2024-04-18T11:24:09-04:00 | |
| 3150787 | BUCHANAN INGERSOLL & ROONEY PC 72522a53-10c5-49d5-9263-000060cd32f4 | Q1 | BUCHANAN INGERSOLL & ROONEY PC | 55291 | GENERIC ANIMAL DRUG ALLIANCE | 2024 | first_quarter | MED | Strategy development and implementation of federal government relations initiatives relating to generic animal drug industry. H.R. 1683, the Generic Animal Drug Advancement Act, all provisions; H.R. 1418, the Animal Drug User Fee Amendments of 2023, all provisions | Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2024-04-18T11:37:51-04:00 | |
| 3150821 | SPINA BIFIDA ASSOCIATION OF AMERICA 40bc35c7-a7ea-4181-b897-b62404dfdeec | Q1 | SPINA BIFIDA ASSOCIATION OF AMERICA | 46665 | SPINA BIFIDA ASSOCIATION OF AMERICA | 2024 | first_quarter | MED | Appropriations | Centers For Disease Control & Prevention (CDC),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE | 75647 | 0 | 0 | 2024-04-18T11:44:04-04:00 | |
| 3150994 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. f0f2cca4-77ae-450d-b217-92c3cd305222 | Q1 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. | 8511 | DEFENSE HEALTH RESEARCH CONSORTIUM | 2024 | first_quarter | MED | HR4365/S2587, FY24 Defense Appropriations Act, Defense Health Research Programs HR2882 Further Consolidated Appropriations Act of FY2024 | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2024-04-18T12:22:11-04:00 | |
| 3151016 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 7fcb2c65-2448-47a5-b008-85047f997cb3 | Q1 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. | 8511 | PANCREATIC CANCER ACTION NETWORK (PANCAN) | 2024 | first_quarter | MED | HR 4365/S 2587, FY24 Defense Appropriations Act, Peer-Reviewed Pancreatic Cancer Research Program; HR 5894/S 2624, FY24 Labor HHS Education Act, NIH research on pancreatic cancer HR2882 Further Consolidated Appropriations Act of FY2024 | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2024-04-18T12:25:51-04:00 | |
| 3151039 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 2acec799-6dc1-464b-867e-17197bf1a085 | Q1 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. | 8511 | FOUNDATION FOR PERIPHERAL NEUROPATHY | 2024 | first_quarter | MED | HR 4365/S 25, FY24 Defense Appropriations Act, DoD funding for peripheral neuropathy research; HR 5894/S 2624, FY24 Labor HHS Education Appropriations Act, NIH research on peripheral neuropathy HR2882 Further Consolidated Appropriations Act of FY2024 | HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE | 20000 | 0 | 0 | 2024-04-18T12:27:30-04:00 | |
| 3151048 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 98832917-56d5-4291-906e-efd06afa8eff | Q1 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. | 8511 | TUBEROUS SCLEROSIS ALLIANCE | 2024 | first_quarter | MED | HR 4365/S 2587, FY24 Defense Appropriations Act, Tuberous Sclerosis Complex Research Program; HR5894/S 2624, FY24 Labor HHS Education Act, NIH and CDC funding for tuberous sclerosis complex research and surveillance. HR2882 Further Consolidated Appropriations Act of FY2024 | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2024-04-18T12:30:04-04:00 | |
| 3151054 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 89dca159-6c72-4d90-9fc7-303b7994087e | Q1 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. | 8511 | KIDNEYCAN | 2024 | first_quarter | MED | HR 5894/S 2624, FY24 Labor-HHS-Education Appropriations Act, kidney cancer research at NIH HR2882 Further Consolidated Appropriations Act of FY2024 | HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE | 20000 | 0 | 0 | 2024-04-18T12:31:16-04:00 | |
| 3151057 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. ddcbdddf-31e6-4590-8cbc-f8a93855179f | Q1 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. | 8511 | VHL ALLIANCE | 2024 | first_quarter | MED | HR 4365/S 2587, FY24 Defense Appropriations Act, DoD research on Von Hippel-Lindau syndrome; HR 5894/S 2624, FY24 Labor HHS Education Act, NIH research on Von Hippel-Lindau syndrome. | HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2024-04-18T12:32:29-04:00 | |
| 3151078 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 79d456fc-1172-4f17-b598-2b0afdc7cb6d | Q1 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. | 8511 | NATIONAL CMV FOUNDATION | 2024 | first_quarter | MED | HR 4365/S 2587, FY24 Defense Appropriations Act, DoD research on congential CMV; HR 5894/S 2624, FY24 Labor HHS Education Act, NIH research on CMV and CDC and HRSA support for CMV testing and surveillance; HR7542/S3757, Stop CMV Act HR2882 Further Consolidated Appropriations Act of FY2024 | HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2024-04-18T12:36:46-04:00 | |
| 3151086 | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. 164823e3-cc82-4561-8dc3-3abc72840a15 | 1A | CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C. | 8511 | DEFENSE HEALTH RESEARCH CONSORTIUM | 2024 | first_quarter | MED | HR4365/S2587, FY24 Defense Appropriations Act, Defense Health Research Programs HR2882 Further Consolidated Appropriations Act of FY2024 | HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2024-04-18T12:37:57-04:00 | |
| 3151177 | THE AMERICAN OCCUPATIONAL THERAPY ASSOCIATION, INC. (AOTA) 9d1ba7f9-7384-4e8f-a23d-f84f338fd4ab | Q1 | THE AMERICAN OCCUPATIONAL THERAPY ASSOCIATION, INC. (AOTA) | 2970 | THE AMERICAN OCCUPATIONAL THERAPY ASSOCIATION, INC. (AOTA) | 2024 | first_quarter | MED | none | 189000 | 0 | 0 | 2024-04-18T12:57:15-04:00 | ||
| 3151183 | BUCHANAN INGERSOLL & ROONEY PC 5a27fe3a-137b-4228-8975-d1eabd9e64e4 | Q1 | BUCHANAN INGERSOLL & ROONEY PC | 55291 | VIVANT BEHAVIORAL HEALTHCARE | 2024 | first_quarter | MED | Monitor, evaluate and respond on issues related to residential treatment centers | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2024-04-18T12:57:35-04:00 | |
| 3151198 | BUCHANAN INGERSOLL & ROONEY PC 847513bc-7f6b-4776-baee-726358b40ed6 | Q1 | BUCHANAN INGERSOLL & ROONEY PC | 55291 | SYNGAP1 FOUNDATION | 2024 | first_quarter | MED | Develop and execute a government relations strategy aligning SYNGAP1s agenda with the current environment in Washington, D.C. | Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2024-04-18T13:00:26-04:00 | ||
| 3151511 | NEW LANTERN, LLC 19f0dc52-0297-43cb-81ac-5dbe12a35c8b | Q1 | NEW LANTERN, LLC | 401105809 | STEEL JUPITER, INC. | 2024 | first_quarter | MED | Inquiries and discussions related to COVID-19, virus and health protection, and small business. | Commerce, Dept of (DOC),Energy, Dept of,Health & Human Services, Dept of (HHS),SENATE,Small Business Administration (SBA),White House Office | 20000 | 0 | 0 | 2024-04-18T13:41:30-04:00 |
Advanced export
JSON shape: default, array, newline-delimited, object
CREATE TABLE lobbying_activities (
id INTEGER PRIMARY KEY,
filing_uuid TEXT NOT NULL,
filing_type TEXT NOT NULL,
registrant_name TEXT NOT NULL,
registrant_id INTEGER,
client_name TEXT NOT NULL,
filing_year INTEGER NOT NULL,
filing_period TEXT NOT NULL,
issue_code TEXT,
specific_issues TEXT,
government_entities TEXT,
income_amount INTEGER,
expense_amount INTEGER,
is_no_activity INTEGER DEFAULT 0,
is_termination INTEGER DEFAULT 0,
received_date TEXT,
CONSTRAINT fk_activity_filing FOREIGN KEY (filing_uuid)
REFERENCES lobbying_filings_raw(filing_uuid)
);
CREATE INDEX idx_act_client_name ON lobbying_activities(client_name COLLATE NOCASE);
CREATE INDEX idx_act_issue_code ON lobbying_activities(issue_code);
CREATE INDEX idx_act_filing_year ON lobbying_activities(filing_year);
CREATE INDEX idx_act_filing_uuid ON lobbying_activities(filing_uuid);